Centre for Translational Medicine, Semmelweis University, Budapest, 1085, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, 7623, Hungary.
Sci Rep. 2024 May 10;14(1):10725. doi: 10.1038/s41598-024-61543-z.
Despite a lack of evidence, patients are often not fed for 48-96 h after upper gastrointestinal bleeding (UGIB); however, many trials have demonstrated the benefits of early nutrition (EN). We conducted a meta-analysis of randomized controlled trials (RTCs) to evaluate the outcomes of EN compared to delayed nutrition (DN) after UGIB. The protocol was registered on PROSPERO (CRD42022372306). PubMed, Embase, CENTRAL, Scopus, and Web of Science were searched on the 27th of April 2024 to identify eligible RCTs. The primary outcomes were early (within 7 days) and late (within 30-42 days) mortality and rebleeding. Pooled risk ratios (RR), mean differences (MD), and corresponding 95% confidence intervals (CI) were calculated using a random-effects model. A total of 10 trials with 1051 patients were included in the analysis. Early mortality was not significantly different between the two groups (RR 1.20, CI 0.85-1.71, I = 0%), whereas late mortality was reduced to a clinically relevant extent in the EN group (RR 0.61, CI 0.35-1.06, I = 0%). When comparing the two groups, we found no significant difference in terms of early and late rebleeding (RR 1.04, CI 0.66-1.63, I = 0% and RR 1.16, CI 0.63-2.13, I = 0%, respectively). Our analysis also showed that the length of hospital stay was reduced in the EN group compared to the DN group (MD -1.22 days, CI: -2.43 to -0.01, I = 94%). In conclusion, compared with DN, EN (within 24 h) appears to be a safe intervention and could reduce the length of hospital stay without increasing the risk of complications after UGIB.
尽管缺乏证据,但在上消化道出血 (UGIB) 后,患者通常会禁食 48-96 小时;然而,许多试验已经证明早期营养 (EN) 的益处。我们对随机对照试验 (RTC) 进行了荟萃分析,以评估与 UGIB 后延迟营养 (DN) 相比,EN 的结果。该方案已在 PROSPERO(CRD42022372306)上注册。我们于 2024 年 4 月 27 日在 PubMed、Embase、CENTRAL、Scopus 和 Web of Science 上进行了检索,以确定合格的 RCT。主要结局是早期(7 天内)和晚期(30-42 天内)死亡率和再出血。使用随机效应模型计算汇总风险比 (RR)、均数差 (MD) 和相应的 95%置信区间 (CI)。共有 10 项试验纳入了 1051 名患者。两组之间的早期死亡率无显著差异(RR 1.20,CI 0.85-1.71,I=0%),但 EN 组的晚期死亡率显著降低(RR 0.61,CI 0.35-1.06,I=0%)。在比较两组时,我们发现早期和晚期再出血没有显著差异(RR 1.04,CI 0.66-1.63,I=0%和 RR 1.16,CI 0.63-2.13,I=0%)。我们的分析还表明,与 DN 相比,EN 组(24 小时内)的住院时间缩短(MD-1.22 天,CI:-2.43 至-0.01,I=94%)。总之,与 DN 相比,EN(24 小时内)似乎是一种安全的干预措施,可在不增加 UGIB 后并发症风险的情况下缩短住院时间。